Literature DB >> 21187081

Cyclooxygenase-2 in oncogenesis.

Maria Teresa Rizzo1.   

Abstract

Compelling experimental and clinical evidence supports the notion that cyclooxygenase-2, the inducible isoform of cyclooxygenase, plays a crucial role in oncogenesis. Clinical and epidemiological data indicate that aberrant regulation of cyclooxygenase-2 in certain solid tumors and hematological malignancies is associated with adverse clinical outcome. Moreover, findings extrapolated from experimental studies in cultured tumor cells and animal tumor models indicate that cyclooxygenase-2 critically influences all stages of tumor development from tumor initiation to tumor progression. Cyclooxygenase-2 elicits cell-autonomous effects on tumor cells resulting in stimulation of growth, increased cell survival, enhanced tumor cell invasiveness, stimulation of neovascularization, and tumor evasion from the host immune system. Additionally, the oncogenic effects of cyclooxygenase-2 stem from its unique ability to impact tumor cell surroundings and create a proinflammatory environment conducive for tumor development, growth and progression. The initial enthusiasm generated by the availability of cyclooxygenase-2 selective inhibitors for cancer prevention and therapy has been lessened by the severe cardiovascular adverse side effects associated with their long-term use, as well as by the mixed results of recent clinical trials evaluating the efficacy of cyclooxygenase-2 inhibitors in adjuvant chemotherapy. Therefore, our ability to efficiently target the oncogenic effects of cyclooxygenase-2 for therapeutic and preventive purposes strictly depends on a better understanding of the spatial and temporal aspects of its activation in tumor cells along with a clearer elucidation of the signaling networks whereby cyclooxygenase-2 affects tumor cells and their interactions with the tumor microenvironment. This knowledge has the potential of leading to the identification of novel cyclooxygenase-2-dependent molecular and signaling networks that can be exploited to improve cancer prevention and therapy.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21187081     DOI: 10.1016/j.cca.2010.12.026

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  49 in total

Review 1.  Cyclooxygenase- and lipoxygenase-mediated DNA damage.

Authors:  N Speed; I A Blair
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 2.  Cyclooxygenases and lipoxygenases in cancer.

Authors:  Claus Schneider; Ambra Pozzi
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

3.  Cyclooxygenase-2 polymorphisms and bladder cancer risk: a meta-analysis based on case-control studies.

Authors:  Guo-Xing Wan; Ping Chen; Xiong-Jie Yu; Quan-Shu Di; Yuan-Dong Yu; Jin-Hua Lei; Yun-Yan Tai; Feng-Jun Cao
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 4.  Therapeutic implications of disorders of cell death signalling: membranes, micro-environment, and eicosanoid and docosanoid metabolism.

Authors:  J Davidson; D Rotondo; M T Rizzo; H A Leaver
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 5.  Tristetraprolin: roles in cancer and senescence.

Authors:  Christina R Ross; Sarah E Brennan-Laun; Gerald M Wilson
Journal:  Ageing Res Rev       Date:  2012-02-24       Impact factor: 10.895

Review 6.  Possible link between cyclooxygenase-inhibiting and antitumor properties of propofol.

Authors:  Takefumi Inada; Kozue Kubo; Koh Shingu
Journal:  J Anesth       Date:  2011-05-25       Impact factor: 2.078

Review 7.  The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis.

Authors:  Josiah Ochieng; Gladys N Nangami; Olugbemiga Ogunkua; Isabelle R Miousse; Igor Koturbash; Valerie Odero-Marah; Lisa J McCawley; Pratima Nangia-Makker; Nuzhat Ahmed; Yunus Luqmani; Zhenbang Chen; Silvana Papagerakis; Gregory T Wolf; Chenfang Dong; Binhua P Zhou; Dustin G Brown; Anna Maria Colacci; Roslida A Hamid; Chiara Mondello; Jayadev Raju; Elizabeth P Ryan; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Hosni K Salem; Amedeo Amedei; Rabeah Al-Temaimi; Fahd Al-Mulla; William H Bisson; Sakina E Eltom
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

8.  Disruption of CTCF/cohesin-mediated high-order chromatin structures by DNA methylation downregulates PTGS2 expression.

Authors:  J Y Kang; S H Song; J Yun; M S Jeon; H P Kim; S W Han; T Y Kim
Journal:  Oncogene       Date:  2015-02-23       Impact factor: 9.867

9.  hnRNPA2/B1 activates cyclooxygenase-2 and promotes tumor growth in human lung cancers.

Authors:  Yang Xuan; Jingshu Wang; Liying Ban; Jian-Jun Lu; Canhui Yi; Zhenglin Li; Wendan Yu; Mei Li; Tingting Xu; Wenjing Yang; Zhipeng Tang; Ranran Tang; Xiangsheng Xiao; Songshu Meng; Yiming Chen; Quentin Liu; Wenlin Huang; Wei Guo; Xiaonan Cui; Wuguo Deng
Journal:  Mol Oncol       Date:  2015-11-30       Impact factor: 6.603

Review 10.  Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview.

Authors:  Simone Brivio; Massimiliano Cadamuro; Luca Fabris; Mario Strazzabosco
Journal:  Gene Expr       Date:  2017-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.